CNTX Profile
Context Therapeutics Inc., a clinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, focuses on developing innovative therapies for women's cancers. Founded in 2015, the company is at the forefront of addressing significant unmet needs in the oncology field, particularly for female patients in the United States. Context Therapeutics is dedicated to advancing novel treatments that target specific molecular pathways implicated in cancer progression.
The company's flagship product candidate, Onapristone Extended Release (ONA-XR), is a potent and selective antagonist of the progesterone receptor. ONA-XR aims to address resistance mechanisms associated with various cancer treatments, including anti-estrogen therapies, in female hormone-dependent cancers. This compound is designed to enhance treatment efficacy by targeting the progesterone receptor, which plays a critical role in the growth and proliferation of certain cancers.
In addition to ONA-XR, Context Therapeutics is developing CLDN6xCD3 bispecific antibody (bsAb), a cutting-edge therapeutic approach that combines anti-CD3 and anti-Claudin 6 (CLDN6) antibodies. This bispecific monoclonal antibody is designed to redirect T-cell-mediated cytotoxicity towards cancer cells expressing CLDN6, a protein overexpressed in various malignancies. The development of CLDN6xCD3 bsAb is supported by a collaboration and licensing agreement with Integral Molecular, Inc., focusing on gynecologic cancers.
Context Therapeutics' innovative pipeline reflects its commitment to addressing critical challenges in women's oncology. By leveraging advanced molecular targeting and collaborative partnerships, the company aims to deliver transformative therapies that can significantly impact the treatment landscape for female cancers.
|
